iN1011-N17

iN1011-N17 is an oral small molecule drug candidate developed by iN Therapeutics. It acts as a selective inhibitor of the voltage-gated sodium channel Nav1.7, also known as Sodium channel protein type 9 subunit alpha, a validated target for pain modulation. By inhibiting Nav1.7, iN1011-N17 aims to provide non-opioid analgesia for various chronic and neuropathic pain conditions, including osteoarthritis and post-herpetic neuralgia. The drug has demonstrated favorable pharmacokinetics in preclinical studies and superior efficacy compared to NSAIDs in animal models of osteoarthritis pain. As of 2024, it is undergoing Phase 1 clinical trials in Australia for indications such as chronic pain, musculoskeletal pain, neuralgia (including postherpetic neuralgia), neuropathic pain, and osteoarthritis[1][4][5][6].

Other names

aneratrigine mesilateaneratrigine mesylate